A controversy is swirling at a Texas university. The trigger? A flowchart. On Dec. 1, the new chancellor of the Texas Tech University system sent professors a diagram laying out a chain of approval ...

Though most players enjoy Minecraft as a regular survival game, it is a massive sandbox that has loads of technical moving parts that are constantly at work. A few enthusiasts and mod developers like ...

The housing market keeps getting worse. Home prices have risen more than 50 percent since the start of the pandemic. About a third of Americans households now spend more than 30 percent of their ...

Bengaluru: Meesho has pulled ahead of its consumer internet peers on free cash flow in FY25, underscoring a shift in India’s e-commerce sector from chasing growth to focusing on capital-efficient ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

"Walk My Walk" by Breaking Rust is No. 1 on the 'Billboard' Country Digital Song Sales chart Jack Irvin has over five years of experience working in digital journalism, and he’s worked at PEOPLE since ...

According to Billboard’s "Country Digital Song Sales" chart, the No. 1 song in the U.S. is "Walk My Walk" by Breaking Rust—an artist that was created by artificial intelligence (AI). Newsweek ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Current political and economic issues succinctly explained. Sign up to receive CFR President Mike Froman’s analysis on the most important foreign policy story of the week, delivered to your inbox ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...